NCT05185505 - Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

October 31, 2027

Conditions

Hepatocellular CarcinomaHepatocellular Cancer

Interventions

DRUG

Atezolizumab

1200 mg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period

DRUG

Bevacizumab

15 mg/kg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period

Trial Locations (1)

RECRUITING

Houston Methodist Research Institute, Houston